BeOne Medicines AG (ONC)
| Market Cap | 35.17B |
| Revenue (ttm) | 5.34B |
| Net Income (ttm) | 286.93M |
| Shares Out | 110.94M |
| EPS (ttm) | 2.47 |
| PE Ratio | 128.34 |
| Forward PE | 56.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 364,133 |
| Open | 318.66 |
| Previous Close | 322.37 |
| Day's Range | 314.23 - 323.24 |
| 52-Week Range | 196.45 - 385.22 |
| Beta | 0.52 |
| Analysts | Strong Buy |
| Price Target | 377.33 (+19.04%) |
| Earnings Date | Feb 26, 2026 |
About ONC
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for ONC stock is "Strong Buy." The 12-month stock price target is $377.33, which is an increase of 19.04% from the latest price.
News
BeiGene Non-GAAP EPS of $1.95 beats by $0.65, revenue of $1.5B beats by $50M
BeiGene (ONC) Q4 Earnings Preview: Revenue Set for Growth
BeiGene (ONC) Q4 Earnings Preview: Revenue Set for Growth
BeiGene Q4 2025 Earnings Preview
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today ...
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today ...